Basilea-Astellas' antifungal treatment gets orphan status from FDA

05/29/2013 | Pharmaceutical Business Review Online

The FDA granted orphan-drug designation to Basilea Pharmaceutica and Astellas Pharma's experimental antifungal isavuconazole as a treatment for invasive aspergillosis. The intravenous and oral-broad spectrum drug is in late-stage studies for severe invasive fungal infections.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA